News Semaglutide scores again, this time in heart failure The list of benefits for Novo Nordisk's semaglutide keeps getting longer.
News Novartis pulls plug on landmark UK cholesterol trial ORION-17 study has been abandoned, with Novartis opting instead for a smaller global trial.
News FDA rejects Cytokinetics’ heart failure drug Firm will request a meeting with FDA, but may have to switch focus to folow-up drug aficamten.
News Abbott survey finds digital divide for patients, physicians Abbott's third report highlights disparities in digital health tool perceptions linger still.
R&D JP Morgan 2023 – Claudia Ulbrich Last month, pharmaphorum sat down with Claudia Ulbrich, CEO of Germany-based Cardior.
News NewAmsterdam's CETP renaissance gathers pace NewAmsterdam Pharma's bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib.
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
